Saad Khanani

Partner

Silicon Valley
saad.khanani@lw.com
+1.650.463.4665

INDUSTRIES

  • Technology

BAR QUALIFICATIONS

  • California

EDUCATION

  • JD, Columbia University School of Law, 2008
  • BA in Economics, Yale University, 2002

PROFILE

Saad Khanani advises public and private companies and venture capital and private equity firms in the technology, life sciences, and other growth industries.

Saad helps public and private technology and life sciences companies, as well as institutional investors navigate a range of corporate transactions, including mergers and acquisitions and investments. He also advises emerging and growth companies on formation, corporate governance, securities law, and transactional matters.

Saad guides clients through complex transactions and growth initiatives with business-oriented advice. He draws upon his prior experience as the founder of an apparel business and a management consultant at McKinsey & Company — where he advised senior leadership at technology companies and federal government agencies.

Saad previously worked in Latham’s office in the United Arab Emirates with a practice focused on general corporate and technology transactions matters. In addition to his commercial work, Saad maintains a pro bono practice, and is an active contributor to Latham’s training and development, recruiting, and diversity programs.

Saad was a James Kent Scholar and a Harlan Fiske Stone Scholar and member of the Columbia Business Law Review and the Faculty Rules Committee while attending Columbia University School of Law.

EXPERIENCE

Mergers & Acquisitions

Saad's public and private mergers and acquisitions and strategic transaction practice has included advising:

Technology

  • Apex Technology Acquisition Corporation in its pending US$2 billion acquisition of AvePoint
  • Bitwise Asset Management in Acquisition of ETC Group
  • Bridgepoint Advisors in its acquisition of Calypso Technology
  • Cloudways in its acquisition by DigitalOcean
  • Convex Labs in acquisition by ServiceTitan
  • Duolingo in its acquisition of Gunner
  • eResearchTechnology in its sale to Nordic Capital
  • Evernote in its acquisition by Bending Spoons
  • Extreme Networks in its US$272 million acquisition of Aerohive Networks
  • Facebook in its strategic acquisitions of BigBox VR, Giphy, GrokStyle, Kustomer, Within, and other technology companies
  • Hightower in its strategic combination with VTS
  • Integrated Device Technology in its US$250 million acquisition of GigPeak
  • IXYS in its US$750 million sale to Littelfuse
  • Joby Aviation in its US$5 billion business combination with Reinvent Technology Partners
  • Ka'ena Corporation in its acquisition by T-Mobile
  • Layr Labs on its acquisition of Rio Network.
  • Mellanox Technologies in its US$6.9 billion sale to NVIDIA Corporation
  • NVIDIA in its:
    • Terminated acquisition of Arm
    • Pending acquisition of Run:ai
    • Completed acquisitions of Bright Computing, DeepMap, and Oski
  • Plaid in its acquisition of Cognito
  • Postmates in its US$2.65 billion sale to Uber
  • Planet Labs in its US$2.8 billion business combination with dMY Technology Group IV
  • Square in its acquisition of:
    • Verse Technologies
    • Dessa
    • Eloquent Labs
  • SRS Acquiom in its sale to Lovell Minnick Partners
  • Upside Foods in its acquisition of Cultured Decadence
  • Vacasa, a Silver Lake portfolio company, in its acquisition of TurnKey Vacation Rentals

Healthcare and Life Sciences

  • Alliance HealthCare Services in connection with the acquisition by Tahoe Investment Group
  • Blue Sprig Holdings on the acquisition of Trumpet Behavioral Health
  • Relievant MedSystems on its acquisition by Boston Scientific
  • Encore Vision in its US$465 million acquisition by Novartis AG
  • Goldman Sachs in its:
    • Acquisition of Xpress Wellness
    • Investments in Ajax Therapeutics, Alterome Therapeutics, Attovia, Nested Therapeutics, Rapport Therapeutics, and TORL BioTherapeutics Landmark Health in its sale to General Atlantic
  • Menlo Therapeutics in its US$390.5 million acquisition of Foamix Pharmaceuticals
  • Relypsa in its US$1.5 billion sale to Galenica AG
  • Revolution Medicines in its acquisition of Warp Drive Bio and other strategic transactions

Venture Capital

Saad regularly represents venture capital and private equity firms in connection with private and public investments, acquisitions, and divestitures. His clients include:

  • Andreessen Horowitz
  • Dragoneer Investment Group
  • Eclipse Ventures
  • Goldman Sachs
  • GreatPoint Ventures
  • KKR
  • SoftBank

Emerging Companies and Public Company Representation

Saad advises public companies in corporate governance matters and strategic investments and emerging and growth companies in formation, corporate governance, securities law, and transactional matters. His experience includes advising:

  • AMD
  • BlueSprig Pediatrics
  • Calysta
  • CorneaGen
  • CrossoverHealth
  • EchoNous
  • Evergent Technologies
  • Facebook
  • Hazel Health
  • Memphis Meats
  • Plaid
  • Square
  • Synack
  • Thumbtack